Abstract
Trastuzumab, a human epidermal growth factor receptor 2 (HER2) inhibitor, is a targeted therapy for HER2-positive cancer. Trastuzumab originator, available in intravenous (IV) and subcutaneous (SC) formulations, can be a significant financial burden for health systems. Following the approval of IV trastuzumab biosimilar (trastuzumab-qyyp) which is less expensive and is not clinically meaningfully different from the originator, the potential savings for payers and hospitals may be significant. This analysis estimated the cost-savings of adding trastuzumab-qyyp for the management of HER2-overexpressing breast and gastric cancer, and gastroesophageal junction (GEJ) adenocarcinoma from French payer and buyer perspectives.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
